Pharming announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST® for Prophylaxis of Hereditary Angioedema AttacksWednesday, January 17, 2018
RUCONEST® is currently approved for the treatment of acute attacks in adult and adolescent patients with HAE. If approved for this new indication, RUCONEST® would become the first C1 inhibitor therapy that would be approved for both acute treatment and prophylaxis of HAE attacks.
ProQR announces proposed underwritten public offering of ordinary shares
HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene‑Verordnung (TAV) in Germany
ProQR announces positive interim results from phase 1/2 clinical trial of QR-110 in LCA10 patients, and plans to start a phase 2/3 pivotal trial